Sun Pharma to launch range of Brivaracetam drug for epilepsy treatment

Sun Pharma's new drug is approved DGCI as an adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.Long-term studies indicate that the response obtained with the use of Brivaracetam is sustained, with favourable tolerability profile and compliance to the treatment